New drug for common liver disease improves liver health

On November 7,¬†2014, the NIH¬†reported that “the FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.” To learn more, click here.

Filed Under: General

About the Author: publications@snma.org

RSSComments (0)

Trackback URL

Comments are closed.